

**Committee Name:**

**Senate Committee – Privacy, Electronic Commerce and Financial Institutions  
(SC–PECFI)**

**Appointments**

01hr\_SC–PECFI\_Appoint\_pt00

**Clearinghouse Rules**

01hr\_SC–PECFI\_CRule\_01–

**Committee Hearings**

01hr\_SC–PECFI\_CH\_pt00

**Committee Reports**

01hr\_SC–PECFI\_CR\_pt00

**Executive Sessions**

01hr\_SC–PECFI\_ES\_pt00

## **Hearing Records**

### **01hr\_ab0464b**

01hr\_sb0000


**Misc.**

01hr\_SC–PECFI\_Misc\_pt01

**Record of Committee Proceedings**

01hr\_SC–PECFI\_RCP\_pt00

# STATE OF WISCONSIN



**Statement of the  
WI Controlled Substances Board  
before the  
Senate Committee on Judiciary, Consumer Affairs,  
And Campaign Finance Reform  
Senator Gary George, Chair**

*Pharmacy Examining Board*

**Statement of Cynthia Benning, RPh, Chair,  
Controlled Substances Board on  
Assembly Bill 464 relating to prohibitions related to  
certain controlled substances and providing a penalty.**

**411 South, State Capitol  
Tuesday, March 5, 2002, 11:00 A.M.**

Chairman George and members of the committee:

Thank you for this opportunity to provide written testimony on the proposed revisions to AB 464 exempting industrial uses for GBL and legitimate medical uses for GBH. I regret I am unable to attend today's hearing, but prior commitments at the hospital prevent it. I am Cindy Benning, RPh the current Chairperson of the Controlled Substances Board and the Pharmacy Examining Board's representative to that board.

The Controlled Substances Board has been examining the prevention of illicit use of GBL and GHB but at the same time providing for their legitimate uses. Both substances have potential for harm to the public.

At its last board meeting the CSB reviewed various examples of draft language which are reflected in the current proposed amendment. Accordingly, the CSB indicated its support for the legislature providing some means to exempt the legitimate industrial uses of GBL and the legitimate medical uses for GHB.

The proposed amendment allows for the industrial use of GBL, which is necessary for several applications by Wisconsin based companies, but puts it into schedule I "when intended for human consumption". This will allow law enforcement to better enforce the penalties for illicit use, but allow for GBL's legitimate industrial use without jeopardizing Wisconsin businesses.

Senate Committee on Judiciary, Consumer Affairs, And Campaign Finance Reform  
Statement of the Controlled Substances Board on 2001 AB 464  
Page 2

In addition, the proposed amendment adds 1,4-Butanediol, “when intended for human consumption”, into schedule I because it cannot be technically covered under the Wisconsin analog law.

Finally, the proposed amendment follows Federal law in that it co-schedules GHB into schedule I and schedule III. The schedule III product is a soon to be released, FDA approved medication for narcolepsy that will benefit many residents of the state of Wisconsin. Without this change, consumers who possess this FDA approved drug in Wisconsin would be in violation of the law because it is currently only listed as a schedule I in Wisconsin.

Thank you for your consideration.

Cindy Benning RPh  
Chairperson of the Wisconsin Controlled Substances Board